Le Lézard15m
Lilly's Kisunlatm (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Eli Lilly and Company today announced that the National Medical Products Administration (NMPA) in China has approved Kisunlatm (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion) ...
The Register-Herald4d
Rockefeller Neuroscience Institute expands access to groundbreaking Alzheimer’s treatment
The WVU Rockefeller Neuroscience Institute (RNI) is providing patients greater statewide and regional access to a ...
Daily Courier4d
WVU neuroscience institute expands access to Alzheimer's treatment
The WVU Rockefeller Neuroscience Institute is providing patients greater statewide and regional access to a groundbreaking ...